A Phase II breast cancer chemoprevention trial of oral α-difluoromethylornithine: Breast tissue, imaging, and serum and urine biomarkers

A double-blind randomized Phase II chemoprevention trial of alpha-difluoromethylornithine (DFMO) was conducted in a group of women at high risk for development of breast cancer. DFMO is an irreversible inhibitor of ornithine decarboxylase, the limiting enzyme of polyamine synthesis that is often up-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2002-10, Vol.8 (10), p.3105-3117
Hauptverfasser:	FABIAN, Carol J, KIMLER, Bruce F, BOYD, Norman F, ARNESON, Dora W, JOHNSON, Karen A, BRADY, Deborah A, MAYO, Matthew S, CHANG, C. H, FERRARO, John A, ZALLES, Carola M, STANTON, Annette L, MASOOD, Shahla, GRIZZLE, William E
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Antineoplastic Agents - therapeutic use Biological and medical sciences Biomarkers, Tumor - metabolism Biopsy, Needle Breast Neoplasms - diagnostic imaging Breast Neoplasms - metabolism Breast Neoplasms - prevention & control Carcinogenesis, carcinogens and anticarcinogens Chemical agents Double-Blind Method Eflornithine - therapeutic use Enzyme Inhibitors - therapeutic use Female Hormones - blood Humans Insulin-Like Growth Factor Binding Protein 3 - blood Insulin-Like Growth Factor I - metabolism Mammography Medical sciences Middle Aged Neoplasm Staging Polyamines - urine Proliferating Cell Nuclear Antigen - blood Quality of Life Receptor, Epidermal Growth Factor Tumor Suppressor Protein p53 - metabolism Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!